These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 34073861)

  • 1. Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices.
    Barbier L; Simoens S; Soontjens C; Claus B; Vulto AG; Huys I
    Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34073861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars in Belgium: a proposal for a more competitive market.
    Moorkens E; Vulto AG; Huys I
    Acta Clin Belg; 2021 Dec; 76(6):441-452. PubMed ID: 32400319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage.
    Maniadakis N; Holtorf AP; Otávio Corrêa J; Gialama F; Wijaya K
    Appl Health Econ Health Policy; 2018 Oct; 16(5):591-607. PubMed ID: 29987759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.
    Vandenplas Y; Simoens S; Van Wilder P; Vulto AG; Huys I
    Front Pharmacol; 2021; 12():644187. PubMed ID: 33953678
    [No Abstract]   [Full Text] [Related]  

  • 5. Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review.
    Vulto AG; Vanderpuye-Orgle J; van der Graaff M; Simoens SRA; Dagna L; Macaulay R; Majeed B; Lemay J; Hippenmeyer J; Gonzalez-McQuire S
    Pharmaceuticals (Basel); 2020 Nov; 13(11):. PubMed ID: 33213079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tendering and biosimilars: what role for value-added services?
    Simoens S; Cheung R
    J Mark Access Health Policy; 2020; 8(1):1705120. PubMed ID: 32002174
    [No Abstract]   [Full Text] [Related]  

  • 7. European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice.
    Barbier L; Simoens S; Vulto AG; Huys I
    BioDrugs; 2020 Dec; 34(6):797-808. PubMed ID: 33063267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption.
    Barbier L; Simoens S; Vulto AG; Huys I
    BioDrugs; 2020 Dec; 34(6):783-796. PubMed ID: 33141421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis.
    Barcina Lacosta T; Vulto AG; Huys I; Simoens S
    Front Pharmacol; 2022; 13():1031910. PubMed ID: 36588696
    [No Abstract]   [Full Text] [Related]  

  • 10. An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain.
    Barcina Lacosta T; Vulto AG; Huys I; Simoens S
    Front Med (Lausanne); 2022; 9():1029040. PubMed ID: 36703896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia.
    Casanova-Juanes J; Mestre-Ferrandiz J; Espín-Balbino J
    Health Policy; 2018 Dec; 122(12):1310-1315. PubMed ID: 30389186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure.
    Vogler S; Schneider P; Zuba M; Busse R; Panteli D
    Front Pharmacol; 2021; 12():625296. PubMed ID: 34248615
    [No Abstract]   [Full Text] [Related]  

  • 13. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
    Dutta B; Huys I; Vulto AG; Simoens S
    BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key drivers for market penetration of biosimilars in Europe.
    Rémuzat C; Dorey J; Cristeau O; Ionescu D; Radière G; Toumi M
    J Mark Access Health Policy; 2017; 5(1):1272308. PubMed ID: 28265349
    [No Abstract]   [Full Text] [Related]  

  • 15. Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment.
    Mestre-Ferrandiz J; Czech M; Smolen JS; Cornes P; Aapro MS; Danese S; Deitch S; Tyldsley H; Foster W; Shah P; Latymer M; Vulto AG
    Expert Rev Pharmacoecon Outcomes Res; 2024 Apr; 24(4):509-519. PubMed ID: 38284223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An international comparative analysis and roadmap to sustainable biosimilar markets.
    Alnaqbi KA; Bellanger A; Brill A; Castañeda-Hernández G; Clopés Estela A; Delgado Sánchez O; García-Alfonso P; Gyger P; Heinrich D; Hezard G; Kakehasi A; Koehn C; Mariotte O; Mennini F; Mayra Pérez-Tapia S; Pistollato M; Saada R; Sasaki T; Tambassis G; Thill M; Werutsky G; Wilsdon T; Simoens S
    Front Pharmacol; 2023; 14():1188368. PubMed ID: 37693908
    [No Abstract]   [Full Text] [Related]  

  • 17. Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices.
    Curto S; Ghislandi S; van de Vooren K; Duranti S; Garattini L
    Health Policy; 2014 Jun; 116(2-3):182-7. PubMed ID: 24602376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market.
    Río-Álvarez I; Cruz-Martos E
    Expert Opin Biol Ther; 2024 Jul; 24(7):583-597. PubMed ID: 38842367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars: How Can Payers Get Long-Term Savings?
    Mestre-Ferrandiz J; Towse A; Berdud M
    Pharmacoeconomics; 2016 Jun; 34(6):609-16. PubMed ID: 26792791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of EU public procurement regulations on tenders in Spain: a study with adalimumab.
    Esplugues FJ; Andújar I; Esplugues JV
    Front Pharmacol; 2024; 15():1447324. PubMed ID: 39364047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.